CN102539736B - 一种cd106阳性细胞、其鉴定、制备方法及应用 - Google Patents
一种cd106阳性细胞、其鉴定、制备方法及应用 Download PDFInfo
- Publication number
- CN102539736B CN102539736B CN201110422541.XA CN201110422541A CN102539736B CN 102539736 B CN102539736 B CN 102539736B CN 201110422541 A CN201110422541 A CN 201110422541A CN 102539736 B CN102539736 B CN 102539736B
- Authority
- CN
- China
- Prior art keywords
- cell
- positive
- stem cell
- mescenchymal stem
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 title claims abstract description 88
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims abstract description 70
- 238000000034 method Methods 0.000 claims abstract description 13
- 210000002826 placenta Anatomy 0.000 claims abstract description 13
- 210000001519 tissue Anatomy 0.000 claims abstract description 11
- 208000024908 graft versus host disease Diseases 0.000 claims abstract description 9
- 230000001900 immune effect Effects 0.000 claims abstract description 6
- 210000000130 stem cell Anatomy 0.000 claims description 53
- 239000001963 growth medium Substances 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 6
- 210000002798 bone marrow cell Anatomy 0.000 claims description 5
- 102100032912 CD44 antigen Human genes 0.000 claims description 4
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 4
- 239000006285 cell suspension Substances 0.000 claims description 4
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 3
- 102100024210 CD166 antigen Human genes 0.000 claims description 3
- 102100037241 Endoglin Human genes 0.000 claims description 3
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 3
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 claims description 3
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims description 3
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 3
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 3
- 102100025304 Integrin beta-1 Human genes 0.000 claims description 3
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- 210000001136 chorion Anatomy 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 230000029087 digestion Effects 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 108010019160 Pancreatin Proteins 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 229940055695 pancreatin Drugs 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 abstract description 16
- 102100037850 Interferon gamma Human genes 0.000 abstract description 15
- 230000001506 immunosuppresive effect Effects 0.000 abstract description 12
- 210000002901 mesenchymal stem cell Anatomy 0.000 abstract description 11
- 230000004069 differentiation Effects 0.000 abstract description 10
- 206010062016 Immunosuppression Diseases 0.000 abstract description 9
- 230000028327 secretion Effects 0.000 abstract description 7
- 230000001464 adherent effect Effects 0.000 abstract description 6
- 210000001185 bone marrow Anatomy 0.000 abstract description 4
- 210000005087 mononuclear cell Anatomy 0.000 abstract description 4
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract description 3
- 238000004115 adherent culture Methods 0.000 abstract 2
- 230000011759 adipose tissue development Effects 0.000 abstract 1
- 229960003130 interferon gamma Drugs 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
- 230000036515 potency Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 33
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 15
- 229960002986 dinoprostone Drugs 0.000 description 15
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 15
- 102100026019 Interleukin-6 Human genes 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 6
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 230000000527 lymphocytic effect Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108010004729 Phycoerythrin Proteins 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101100025201 Mus musculus Msc gene Proteins 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000004252 chorionic villi Anatomy 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000008629 immune suppression Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 108010024164 HLA-G Antigens Proteins 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 229940127215 low-molecular weight heparin Drugs 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004072 osteoblast differentiation Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 210000005059 placental tissue Anatomy 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000000795 Galectin 1 Human genes 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- YGPSJZOEDVAXAB-QMMMGPOBSA-N L-kynurenine Chemical compound OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-QMMMGPOBSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000024340 acute graft versus host disease Diseases 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000009455 aseptic packaging Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 125000000609 carbazolyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000013210 evaluation model Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000002660 stem cell treatment Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 230000009495 transient activation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110422541.XA CN102539736B (zh) | 2011-12-16 | 2011-12-16 | 一种cd106阳性细胞、其鉴定、制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110422541.XA CN102539736B (zh) | 2011-12-16 | 2011-12-16 | 一种cd106阳性细胞、其鉴定、制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102539736A CN102539736A (zh) | 2012-07-04 |
CN102539736B true CN102539736B (zh) | 2015-04-29 |
Family
ID=46347136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110422541.XA Active CN102539736B (zh) | 2011-12-16 | 2011-12-16 | 一种cd106阳性细胞、其鉴定、制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102539736B (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103989708A (zh) * | 2014-05-27 | 2014-08-20 | 中国人民解放军军事医学科学院基础医学研究所 | 一种小鼠急性移植物抗宿主病模型的建立方法 |
CN105483206B (zh) * | 2016-01-06 | 2019-09-13 | 北京汉氏联合生物技术股份有限公司 | 一种用vcam-1检测msc促内皮细胞增殖能力的方法 |
CN105891512A (zh) * | 2016-05-11 | 2016-08-24 | 天津普瑞赛尔生物科技有限公司 | 用于鉴定脐带间充质干细胞的试剂盒 |
PT3551748T (pt) * | 2016-12-12 | 2022-09-29 | Health And Biotech France H&B France | Células estaminais do mesênquima derivadas de tecido perinatal: método de preparação e suas utilizações |
KR20210061328A (ko) * | 2018-06-11 | 2021-05-27 | 헬스 앤드 바이오테크 프랑스 (에이치 앤드 비 프랑스) | 중간엽 줄기 세포로부터 유래된 세포외 소포 |
JPWO2021006316A1 (zh) * | 2019-07-10 | 2021-01-14 | ||
CN110272865A (zh) * | 2019-07-17 | 2019-09-24 | 中国医科大学附属第一医院 | 一种分离提纯骨髓间充质干细胞亚群的方法 |
CN111304166A (zh) * | 2020-02-24 | 2020-06-19 | 南京鼓楼医院 | 一种提高从人脐带间充质干细胞纯化cd106阳性亚群比例的方法 |
CN111534484B (zh) * | 2020-05-15 | 2022-10-11 | 北京汉氏干细胞科技有限公司 | 一种制备cd106高表达间充质干细胞的方法、间充质干细胞及其应用和定向培养基 |
CN114085812B (zh) * | 2022-01-12 | 2022-04-19 | 铂生卓越生物科技(北京)有限公司 | 一种高表达cd106和/或cd142表达降低的间充质干细胞群、其制备方法及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1809632A (zh) * | 2003-03-28 | 2006-07-26 | 成血管细胞系统公司 | 血管周围间充质前体细胞 |
JP2008220334A (ja) * | 2007-03-15 | 2008-09-25 | Kyoto Univ | 間葉系幹細胞の分化能マーカーとしてのcd106の使用 |
CN101748096A (zh) * | 2008-12-17 | 2010-06-23 | 北京汉氏联合生物技术有限公司 | 亚全能干细胞、其制备方法及其用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2021373A4 (en) * | 2006-05-31 | 2010-06-02 | Hanwa Chemical Corp | MONOCLONAL ANTIBODY VCAM-1 SPECIFIC |
WO2008129563A2 (en) * | 2007-04-23 | 2008-10-30 | Stempeutics Research Private Limited, | Human mesenchymal stem cells and preparation thereof |
-
2011
- 2011-12-16 CN CN201110422541.XA patent/CN102539736B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1809632A (zh) * | 2003-03-28 | 2006-07-26 | 成血管细胞系统公司 | 血管周围间充质前体细胞 |
JP2008220334A (ja) * | 2007-03-15 | 2008-09-25 | Kyoto Univ | 間葉系幹細胞の分化能マーカーとしてのcd106の使用 |
CN101748096A (zh) * | 2008-12-17 | 2010-06-23 | 北京汉氏联合生物技术有限公司 | 亚全能干细胞、其制备方法及其用途 |
Non-Patent Citations (5)
Title |
---|
Chondrogenic potential of subpopulations of cells expressing mesenchymal stem cell markers derived from human synovial membranes;Arufe MC,et al;《Journal of Cellular Biochemistry》;20101101;第111卷(第4期);摘要、第834页右栏第4行至第835页右栏倒数第4行,第836页左栏第14-30行,第837页左栏第15-46行,右栏第7-17行,第839页右栏第7-26行,图1-3,5 * |
Inflammatory Cytokine-Induced Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 in Mesenchymal Stem Cells Are Critical for Immunosuppression;Guangwen Ren,et al;《J Immunol.》;20100301;第184卷(第5期);摘要,Page 1倒数第5-1行,Page 2第11-41行,Page 5第36-37行,Page 6第36-45行,Page 7第17-18行,倒数第6-2行 * |
Modulated expression of adhesion molecules and galectin-1: Role during mesenchymal stromal cell immunoregulatory functions;Mehdi Najar,et al;《Experimental Hematology》;20101031;第38卷(第10期);922–932 * |
人胎盘源间充质干细胞向成骨细胞和脂肪细胞分化的实验研究;翁震等;《苏州大学学报(医学版)》;20081125;第28卷(第06期);摘要,第1.2.1-1.2.7节,2.2-2.5李, * |
人胎盘源间充质干细胞的生物学特性及其对T细胞负性协同抑制作用;古彦铮;《中国优秀硕士学位论文全文数据库医药卫生科技辑》;20091015(第10期);摘要、正文第21页第1-4行 * |
Also Published As
Publication number | Publication date |
---|---|
CN102539736A (zh) | 2012-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102539736B (zh) | 一种cd106阳性细胞、其鉴定、制备方法及应用 | |
Liu et al. | Systemic infusion of mesenchymal stem cells improves cell-based bone regeneration via upregulation of regulatory T cells | |
Nakao et al. | Adipose tissue-derived mesenchymal stem cells facilitate hematopoiesis in vitro and in vivo: advantages over bone marrow-derived mesenchymal stem cells | |
Bustos et al. | Activation of human mesenchymal stem cells impacts their therapeutic abilities in lung injury by increasing interleukin (IL)-10 and IL-1RN levels | |
US10646518B2 (en) | Apoptotic bodies | |
Bernardi et al. | Production of human platelet lysate by use of ultrasound for ex vivo expansion of human bone marrow–derived mesenchymal stromal cells | |
CN103756963A (zh) | 一种体外扩增nk细胞的方法 | |
CN108893443A (zh) | 一种细胞因子诱导脐带血自然杀伤细胞的高效扩增方法 | |
Li et al. | Effects of bone marrow mesenchymal stem cells on hematopoietic recovery and acute graft-versus-host disease in murine allogeneic umbilical cord blood transplantation model | |
KR20140040696A (ko) | 간엽줄기세포 및 면역조절 t 세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 | |
CN113181215B (zh) | 一种骨髓间充质干细胞外泌体制剂及促进造血损伤恢复的用途 | |
WO2018030448A1 (ja) | 細胞培養用培地、及び細胞培養方法 | |
CN106282108A (zh) | 一种具有免疫调节功能的脾脏间充质干细胞及其制备方法与应用 | |
Cao et al. | Culture and properties of adipose-derived mesenchymal stem cells: characteristics in vitro and immunosuppression in vivo | |
CN104480069A (zh) | 一种利用外周血分离培养免疫细胞的方法 | |
EP2859092A1 (en) | Therapeutic vaccine for treatment of diabetes type 1 in children, application of the cell sorter and the method of multiplying treg cells to produce therapeutic vaccine for treatment of diabetes type 1 | |
CN115281184B (zh) | 一种间充质干细胞复合冻存液及其制备方法和应用 | |
CN107090434B (zh) | 一种提高cik细胞培养效果的血液抗凝和保存方法 | |
CN102641296B (zh) | 一种抑制免疫及治疗移植物抗宿主病(gvhd)制剂及其制备方法 | |
Ryan et al. | Mesenchymal stem/stromal cell therapy: mechanism of action and host response | |
CN101429496A (zh) | 一种用于人外周血来源造血干细胞的培养基 | |
CN101429495A (zh) | 一种人外周血来源造血干细胞的培养方法 | |
Jammes et al. | Effect of pro-inflammatory cytokine priming and storage temperature of the mesenchymal stromal cell (MSC) secretome on equine articular chondrocytes | |
Otsuka et al. | Regeneration capability of Lin−/c-Kit+/Sca-1+ cells with or without radiation exposure for repopulation of peripheral blood in lethally irradiated mice monitored using Ly5. 1 isotype on days 35, 90, and 270 after transplantation | |
KR102376432B1 (ko) | 말초 혈액으로부터 중간엽 줄기 세포 집단을 생성하는 방법 및 그의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 100176, No. 3, building 1, Kangding street, Beijing economic and Technological Development Zone, Beijing, Daxing District, one or two Patentee after: HEALTH & BIOTECH GROUP Address before: 100176, No. 3, building 1, Kangding street, Beijing economic and Technological Development Zone, Beijing, Daxing District, one or two Patentee before: Beijing Hanshi United Biological Technology Co., Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: CD106-positive cells, and identification and preparation method and application thereof Effective date of registration: 20200313 Granted publication date: 20150429 Pledgee: Beijing Yizhuang International Financing Guarantee Co., Ltd. Pledgor: HEALTH AND BIOTECH FRANCE (H & B FRANCE) Registration number: Y2020990000177 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210928 Granted publication date: 20150429 Pledgee: Beijing Yizhuang International Financing Guarantee Co.,Ltd. Pledgor: HEALTH AND BIOTECH FRANCE (H & B FRANCE) Registration number: Y2020990000177 |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211104 Address after: Room 105, 1st floor, block Q1, building 1, No.1 Kangding street, economic and Technological Development Zone, Daxing District, Beijing Patentee after: Beijing Hanshi Stem Cell Technology Co.,Ltd. Address before: 100176 1st and 2nd floors, building 3, yard 1, Kangding street, Beijing Economic and Technological Development Zone, Daxing District, Beijing Patentee before: HEALTH AND BIOTECH FRANCE (H & B FRANCE) |